{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang X"],"funding":["Natural Science Foundation of Zhejiang Province","National Natural Science Foundation of China","National Key Research and Development Program","Research and Development Program of Zhejiang Province"],"pagination":["e003982"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8906048"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(3)"],"pubmed_abstract":["Backgrounds
In advanced pancreatic ductal adenocarcinoma (PDAC), immune therapy, including immune checkpoint inhibitors, has limited efficacy, encouraging the study of combination therapy.Methods
Tumor necrosis factor receptor 2 (TNFR2) was analyzed via immunohistochemistry, immunofluorescence, western blotting, and ELISAs. The in vitro mechanism that TNFR2 regulates programmed cell death 1 ligand 1 (PD-L1) was investigated using immunofluorescence, immunohistochemistry, flow cytometry, western blotting, and chromatin immunoprecipitation (ChIP). In vivo efficacy and mechanistic studies, using C57BL/6 mice and nude mice with KPC cell-derived subcutaneous and orthotopic tumors, employed antibodies against TNFR2 and PD-L1. Survival curves were constructed for the orthotopic mo"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors."],"pmcid":["PMC8906048"],"funding_grant_id":["81830089","2019C03019","81871925","U20A20378","2019YFC1316000","82071867","2020C03117","LQ22H160044"],"pubmed_authors":["Yang H","Liang T","Jiang H","Ying H","He L","Bai X","Xu J","Li M","Zhang X","Chen W","Lao M","Guo C","Duan Y","Sun K"],"additional_accession":[]},"is_claimable":false,"name":"Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.","description":"Backgrounds
In advanced pancreatic ductal adenocarcinoma (PDAC), immune therapy, including immune checkpoint inhibitors, has limited efficacy, encouraging the study of combination therapy.Methods
Tumor necrosis factor receptor 2 (TNFR2) was analyzed via immunohistochemistry, immunofluorescence, western blotting, and ELISAs. The in vitro mechanism that TNFR2 regulates programmed cell death 1 ligand 1 (PD-L1) was investigated using immunofluorescence, immunohistochemistry, flow cytometry, western blotting, and chromatin immunoprecipitation (ChIP). In vivo efficacy and mechanistic studies, using C57BL/6 mice and nude mice with KPC cell-derived subcutaneous and orthotopic tumors, employed antibodies against TNFR2 and PD-L1. Survival curves were constructed for the orthotopic mo","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-06-02T09:37:43.451Z","creation":"2026-05-26T03:06:28.864Z"},"accession":"S-EPMC8906048","cross_references":{"pubmed":["35260434"],"doi":["10.1136/jitc-2021-003982"]}}